市場調査レポート
商品コード
1323873

細胞治療技術の世界市場:製品タイプ別、プロセス別、細胞タイプ別、エンドユーザー別、地域別-2028年までの予測

Cell Therapy Technologies Market by Product, Process, Cell type, End User, Region - Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 236 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
細胞治療技術の世界市場:製品タイプ別、プロセス別、細胞タイプ別、エンドユーザー別、地域別-2028年までの予測
出版日: 2023年07月27日
発行: MarketsandMarkets
ページ情報: 英文 236 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の細胞治療技術の市場規模は、2023年の42億米ドルから2028年には78億米ドルに達すると予測され、予測期間中のCAGRは13.3%と見込まれています。

細胞ベースの研究に対する政府投資の増加、慢性疾患や感染症の罹患率の上昇、腫瘍関連の細胞治療臨床試験の大幅な減少、細胞治療生産施設のGMP認証の増加などの要因が、市場成長にプラスの影響を与えると考えられます。

世界の細胞治療技術市場は、プロセス別では、細胞加工、細胞保存、流通・ハンドリング、プロセスモニタリング・品質管理に区分されます。2022年の市場シェアは、細胞処理分野が圧倒的でした。細胞加工技術の進歩が市場成長に好影響を与えそうです。

エンドユーザー別では、市場はバイオ製薬・バイオテクノロジー企業、CRO・CMO、研究機関・セルバンクに区分されます。2022年には、バイオ医薬品・バイオテクノロジー企業セグメントが細胞治療技術市場で最大のシェアを占めました。同セグメントは、主要な市場参入企業による細胞治療製造施設の増加や、細胞治療の研究活動への投資の増加など、さまざまな要因により、市場で圧倒的なシェアを占めています。

細胞治療技術市場はアジア太平洋において予測期間中に著しいCAGRで成長すると予測されています。同地域の成長の主な原動力は、細胞ベースの研究に対する政府投資の増加です。ワクチン開発のための研究資金が増加し、疾患プロファイルが変化しているため、中国、インド、日本からの細胞治療機器や製品に対する需要が増加していることが、アジア太平洋地域の市場成長を支えています。さらに、慢性疾患や感染症の罹患率の増加、高齢者人口の増加、ヘルスケアインフラ整備のための政府の取り組みなどは、市場成長にプラスの影響を与えると予想される要素の一部です。

当レポートでは、世界の細胞治療技術市場について調査し、市場の概要とともに、製品タイプ別、プロセス別、細胞タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • 参考価格モデル分析
  • 技術分析
  • バリューチェーン分析
  • サプライチェーン分析
  • 細胞治療技術市場のエコシステム分析
  • 2022年~2023年の主要な会議とイベント
  • 規制分析
  • ポーターのファイブフォース分析
  • 特許分析
  • 主要な利害関係者と購入基準

第6章 細胞治療技術市場、製品別

  • イントロダクション
  • 培地、血清、および試薬
  • 細胞エンジニアリング製品
  • 細胞培養容器
  • 細胞治療装置
  • システムとソフトウェア
  • その他

第7章 細胞治療技術市場、プロセス別

  • イントロダクション
  • 細胞プロセシング
  • 細胞の保存、配布、および取り扱い
  • プロセス監視と品質管理

第8章 細胞治療技術市場、細胞タイプ別

  • イントロダクション
  • T細胞
  • 幹細胞
  • その他

第9章 細胞治療技術市場、エンドユーザー別

  • イントロダクション
  • バイオ医薬品およびバイオテクノロジー企業
  • CRO、CMO
  • 研究機関とセルバンク

第10章 細胞治療技術市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

第12章 企業プロファイル

  • 主要参入企業
    • THERMO FISHER SCIENTIFIC, INC.
    • MERCK KGAA
    • DANAHER CORPORATION
    • LONZA GROUP
    • SARTORIUS AG
    • TERUMO BCT, INC.
    • BECTON DICKINSON AND COMPANY
    • FRESENIUS SE & CO. KGAA
    • AVANTOR, INC.
    • BIO-TECHNE
    • CORNING INCORPORATED
    • FUJIFILM IRVINE SCIENTIFIC
    • MAXCYTE, INC.
  • その他の企業
    • WERUM IT SOLUTIONS
    • ROOSTERBIO, INC.
    • SIRION BIOTECH
    • TRAKCEL
    • L7 INFORMATICS, INC.
    • MILTENYI BIOTEC B.V. & CO. KG
    • STEMCELL TECHNOLOGIES
    • GPI IBERIA(FORMERLY HEMASOFT)
    • MAK-SYSTEM
    • ORGANABIO
    • IXCELLS BIOTECHNOLOGIES
    • WILSON WOLF

第13章 付録

目次
Product Code: BT 6823

The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.

"The process segment held the dominant share in the cell therapy technologies market"

Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022. Advancement in cell processing techniques is likely to have positive impact on the growth of the market.

"Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022."

Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROS & CMOS, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.

"Asia Pacific region is likely to grow at a faster pace."

The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70%, and Demand Side - 30%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Lonza Group (Switzerland)
  • Sartorius AG(Germany)
  • Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
  • Becton, Dickinson & Company (US)
  • Fresenius Se & co. KGaA (Germany)
  • Avantor Inc (US)
  • Bio-Techne (US)
  • Corning Incorporated (US)
  • Fujifilm Irvine Scientific (Japan)
  • Maxcyte Inc. (US)
  • Werum Software & Systems AG (Part of Korber AG) (Germany)
  • Roosterbio Inc. (US)
  • Sirion Biotech Gmbh (Germany)
  • Trakcel (UK)
  • L 7 Informatics Inc. (US)
  • Miltenyi Biotech (Germany)
  • Steamcell Technologies Inc. (Canada)
  • GPI Iberia (Formerly Hemasoft) (Spain)
  • CodexThemes (France)
  • Organabio LLC. (US)
  • Ixcells Biotechnologies (US)
  • Wilson Wolf 2019 Manufacturing Corporation (US)

Research Coverage:

This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process,cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints ( High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.
  • Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the Cell therapy technologies market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and among others in the cell therapy technologies market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
    • FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES
  • 4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022)
    • FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028
    • FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028
  • 4.4 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION)
    • FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022
  • 4.5 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing government investments in cell-based research
    • TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019-2022 (USD MILLION)
      • 5.2.1.2 Rising incidence of chronic and infectious diseases
      • 5.2.1.3 Large number of oncology-related cell therapy clinical trials
    • FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021-2022
      • 5.2.1.4 Increasing GMP certifications for cell therapy production facilities
    • TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of cell-based research and low success rate
    • TABLE 6 COST OF CELL THERAPY EQUIPMENT
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emergence of iPSCs as alternatives to ESCs
      • 5.2.3.2 Increased focus on personalized medicine
      • 5.2.3.3 Increasing partnerships for development of cell therapies
      • 5.2.3.4 Emerging Asian markets
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Survival of small players and new entrants
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
  • 5.4 INDICATIVE PRICING MODEL ANALYSIS
    • TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET
    • FIGURE 26 ECOSYSTEM ANALYSIS
    • TABLE 8 SUPPLY CHAIN ECOSYSTEM
  • 5.9 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 9 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.10 REGULATORY ANALYSIS
    • 5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES
    • 5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 19 CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 DEGREE OF COMPETITION
  • 5.12 PATENT ANALYSIS
    • FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013-JULY 2023
    • TABLE 20 CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS
    • 5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
    • FIGURE 29 KEY BUYING CRITERIA FOR END USERS

6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 21 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 MEDIA, SERA, AND REAGENTS
    • 6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
    • TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 CELL ENGINEERING PRODUCTS
    • 6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
    • TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
    • TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 CELL CULTURE VESSELS
    • 6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS
    • TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 CELL THERAPY EQUIPMENT
    • TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021-2028 (USD MILLION)
    • TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.1 CELL PROCESSING EQUIPMENT
      • 6.5.1.1 Cell processing equipment to dominate market
    • TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.2 SINGLE-USE EQUIPMENT
      • 6.5.2.1 Benefits of single-use equipment to ensure end-user demand
    • TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.5.3 OTHER EQUIPMENT
    • TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 SYSTEMS & SOFTWARE
    • 6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND
    • TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.7 OTHER PRODUCTS
    • TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

  • 7.1 INTRODUCTION
    • TABLE 60 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 7.2 CELL PROCESSING
    • 7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028
    • TABLE 61 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING
    • 7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
    • TABLE 65 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 PROCESS MONITORING & QUALITY CONTROL
    • 7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION
    • TABLE 69 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 70 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)

8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

  • 8.1 INTRODUCTION
    • TABLE 73 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
  • 8.2 T CELLS
    • 8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
    • TABLE 74 CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 STEM CELLS
    • 8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
    • TABLE 78 CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER CELLS
    • TABLE 82 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION)

9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET
    • TABLE 87 CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 CROS & CMOS
    • 9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
    • TABLE 91 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 92 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 RESEARCH INSTITUTES & CELL BANKS
    • 9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
    • TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 96 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 99 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
    • TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Increasing R&D activities to support market growth
    • TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
    • TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Germany to hold largest share of European market
    • TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Favorable funding and investment scenario to drive market
    • TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Availability of government and private support to drive market
    • TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 135 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 136 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth
    • TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 139 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 140 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing funding from private and public organizations to aid market growth
    • TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 144 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 145 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 150 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 152 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 156 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 157 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing cell therapy-based trials to support market growth
    • TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 161 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 162 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Rising geriatric population and growing disease prevalence to drive market
    • TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022
    • TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 167 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Favorable government regulations to support market growth
    • TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 172 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 173 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 178 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 182 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 187 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)
    • TABLE 188 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 34 CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 189 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 35 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
  • 11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
    • TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES)
    • TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
    • TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
  • 11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • 11.7.1 PROGRESSIVE COMPANIES
    • 11.7.2 STARTING BLOCKS
    • 11.7.3 RESPONSIVE COMPANIES
    • 11.7.4 DYNAMIC COMPANIES
    • FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
  • 11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 193 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 194 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
  • 11.9 COMPETITIVE SCENARIO AND TRENDS
    • 11.9.1 PRODUCT LAUNCHES
    • TABLE 195 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
    • 11.9.2 DEALS
    • TABLE 196 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020-APRIL 2023
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 197 CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023

12 COMPANY PROFILES

  • 12.1 KEY MARKET PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 12.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 MERCK KGAA
    • TABLE 199 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.3 DANAHER CORPORATION
    • TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.4 LONZA GROUP
    • TABLE 201 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022)
    • 12.1.5 SARTORIUS AG
    • TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • 12.1.6 TERUMO BCT, INC.
    • TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW
    • FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 BECTON DICKINSON AND COMPANY
    • TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 12.1.8 FRESENIUS SE & CO. KGAA
    • TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
    • FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)
    • 12.1.9 AVANTOR, INC.
    • TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW
    • FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.10 BIO-TECHNE
    • TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW
    • FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022)
    • 12.1.11 CORNING INCORPORATED
    • TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW
    • FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
    • 12.1.12 FUJIFILM IRVINE SCIENTIFIC
    • TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 12.1.13 MAXCYTE, INC.
    • TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW
    • FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022)
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 WERUM IT SOLUTIONS
    • 12.2.2 ROOSTERBIO, INC.
    • 12.2.3 SIRION BIOTECH
    • 12.2.4 TRAKCEL
    • 12.2.5 L7 INFORMATICS, INC.
    • 12.2.6 MILTENYI BIOTEC B.V. & CO. KG
    • 12.2.7 STEMCELL TECHNOLOGIES
    • 12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
    • 12.2.9 MAK-SYSTEM
    • 12.2.10 ORGANABIO
    • 12.2.11 IXCELLS BIOTECHNOLOGIES
    • 12.2.12 WILSON WOLF

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS